In the Basel Area in Northwestern Switzerland you find one of the highest-density clusters in life sciences, nanotechnology, quantum technologies, humanities, and sustainability. This wealth of innovation potential cuts across private and public sectors, with globally renowned multinational enterprises, cutting-edge small and medium sized companies as well as the University of Basel, the University of Applied Sciences, and the Biosystems Science and Engineering Department of the ETH).
Imagine what you could achieve more easily and faster if you knew what skills and facilities are available to you. We aim to facilitate innovation collaborations in the Basel Area across life sciences and technology by fostering low-threshold opportunities for cross-disciplinary exchange. This second of a new workshop series aims to bring together companies of all sizes and researchers from the Basel academic innovation network, creating productive interfaces, joint projects and interdisciplinary collaborations to innovate faster, better.
Researchers will get access to an expanded collaboration network, potential collaborations and use-inspired research. Company scientists and executives will get access to the local academic talent pool and cutting-edge skills and technologies to jointly tackle critical challenges. Participants will get a chance to meet potential collaborators, an understanding of our region´s innovation landscape and insights into innovation opportunities.
InSphero and the D-BSSE: a case study
InSphero is a spin-off company of the D-BSSE and commercializes 3D tissue culture technologies. They collaborate frequently and closely with the lab they emerged from and have been able to translate the outcome of such a collaborative project into a successful commercial product. How do they work together and what is the key to their fruitful collaboration?
- Market access as a key enabler for commercial success
- How to manage market access for products in early development
- Factors influencing price and reimbursement/funding for biopharma products
- Gaining market access in a challenging European environment